All lobbying filings

BROWNSTEIN HYATT FARBER SCHRECK, LLP

BROWNSTEIN HYATT FARBER SCHRECK, LLP filed a Q1 report for NOVAVAX, INC. on April 15, 2026, reporting $50,000 in lobbying income.

Lobbying for NOVAVAX, INC. · Biotechnology company

All filings by BROWNSTEIN HYATT FARBER SCHRECK, LLP · Everything NOVAVAX, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 15, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to federal vaccine programs and vaccine regulatory frameworks. FDA funding and advocacy H.R.4121 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Bills named in this filing 1

H.R. 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.